Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
General Rheumatology
•
JAK Inhibitors
•
Gastroenterology
•
Dermatology
•
Nephrology
Have you utilized JAK inhibitors in patients on dialysis?
Related Questions
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
How would you approach management of retroperitoneal fibrosis causing ureteral compression that has already caused irreversible loss of kidney function?
Would you add immunosuppression for recurrent calcium kidney stones in a patient with sarcoidosis?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
Do you recommend sending an autoimmune work up for patients with recurrent nephrolithiasis and 24 hour urine chemistries consistent with distal renal tubular acidosis?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
How would you approach management of an elderly patient with known mantle cell lymphoma and new diagnosis of cryoglobulinemic vasculitis with mild skin involvement, fatigue, arthralgias but no other major organ involvement?